General Information of Drug (ID: DMXM3B4)

Drug Name
TEI-9874 Drug Info
Indication
Disease Entry ICD 11 Status REF
Allergy 4A80-4A85 Terminated [1]
Cross-matching ID
PubChem CID
9935533
TTD Drug ID
DMXM3B4

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Immunoglobulin E (IgE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ligelizumab DM103O8 Chronic idiopathic urticaria EB00.1 Phase 3 [3]
MEMP1972A DMUMCWS Allergic rhinitis CA08.0 Phase 2 [4]
Xmab-7195 DME7IVL Asthma CA23 Phase 1 [5]
PF-06444752 DM9UZTO Asthma CA23 Phase 1 [6]
MEDI4212 DMBI4EN Asthma CA23 Phase 1 [7]
AVP-13358 DM8CYJ1 Rhinitis FA20 Phase 1 [8]
TAK-201 DM8S173 Allergy 4A80-4A85 Discontinued in Phase 2 [9]
IGE-026 DM16S98 Allergic rhinitis CA08.0 Terminated [10]
D17.4 DMSON1P Myasthenia gravis 8C6Y Investigative [11]
IGEL1.2 DMOU234 Allergy 4A80-4A85 Investigative [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Immunoglobulin E (IgE) TTYJQTF NOUNIPROTAC Modulator [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800012536)
2 Effect of TEI-9874, an inhibitor of immunoglobulin E production, on allergen-induced asthmatic model in rats. Eur J Pharmacol. 2000 Aug 25;402(3):287-95.
3 Clinical pipeline report, company report or official report of Novartis.
4 International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 25, No. 4, 2011
5 Clinical pipeline report, company report or official report of Xencor.
6 ClinicalTrials.gov (NCT01723254) A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis. U.S. National Institutes of Health.
7 A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma. MAbs. 2014 May-Jun;6(3):756-64.
8 Novel 2-(substituted phenyl)benzimidazole derivatives with potent activity against IgE, cytokines, and CD23 for the treatment of allergy and asthma. J Med Chem. 2004 Dec 16;47(26):6451-4.
9 Adecatumumab: an anti-EpCAM monoclonal antibody, from the bench to the bedside. Expert Opin Biol Ther. 2010 Jun;10(6):951-8.
10 IgE inhibition as a therapy for allergic disease. Int Arch Allergy Immunol. 1999 Feb-Apr;118(2-4):112-5.
11 Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.